ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 141 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2022. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $25,119 | -7.0% | 4,032 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $27,014 | +80.2% | 4,032 | +71.1% | 0.00% | 0.0% |
| Q2 2022 | $14,991 | -21.5% | 2,357 | -42.7% | 0.00% | 0.0% |
| Q1 2022 | $19,089 | -79.6% | 4,114 | -47.1% | 0.00% | 0.0% |
| Q3 2021 | $93,713 | -43.0% | 7,777 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $164,484 | -24.6% | 7,777 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $218,145 | +7.9% | 7,777 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $202,202 | -30.1% | 7,777 | 0.0% | 0.00% | -40.0% |
| Q3 2020 | $289,071 | -27.6% | 7,777 | 0.0% | 0.01% | -28.6% |
| Q2 2020 | $399,038 | +62.7% | 7,777 | 0.0% | 0.01% | +40.0% |
| Q1 2020 | $245,209 | -47.1% | 7,777 | 0.0% | 0.01% | -37.5% |
| Q4 2019 | $463,743 | +37.1% | 7,777 | -15.7% | 0.01% | +33.3% |
| Q3 2019 | $338,335 | -5.5% | 9,229 | +19.9% | 0.01% | 0.0% |
| Q2 2019 | $358,111 | +15.9% | 7,698 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $309,075 | -12.7% | 7,698 | 0.0% | 0.01% | -14.3% |
| Q4 2018 | $354,108 | +3.7% | 7,698 | 0.0% | 0.01% | +16.7% |
| Q3 2018 | $341,560 | -99.9% | 7,698 | 0.0% | 0.01% | +20.0% |
| Q2 2018 | $301,684,000 | -23.8% | 7,698 | +40.6% | 0.01% | -16.7% |
| Q1 2018 | $395,935,000 | +109881.9% | 5,474 | 0.0% | 0.01% | +20.0% |
| Q4 2017 | $360,000 | -34.1% | 5,474 | -49.8% | 0.01% | +66.7% |
| Q3 2017 | $546,000 | +8.3% | 10,896 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $504,000 | +30.9% | 10,896 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $385,000 | +323.1% | 10,896 | +17.7% | 0.00% | +200.0% |
| Q2 2016 | $91,000 | -42.0% | 9,258 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $157,000 | -23.8% | 9,258 | 0.0% | 0.00% | -50.0% |
| Q4 2015 | $206,000 | -5.5% | 9,258 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $218,000 | -71.2% | 9,258 | 0.0% | 0.00% | -60.0% |
| Q2 2015 | $757,000 | +54.2% | 9,258 | +74.4% | 0.01% | +25.0% |
| Q1 2015 | $491,000 | +128.4% | 5,307 | 0.0% | 0.00% | +300.0% |
| Q4 2014 | $215,000 | – | 5,307 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |